Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00619879 |
Recruitment Status : Unknown
Verified March 2011 by Ann & Robert H Lurie Children's Hospital of Chicago.
Recruitment status was: Recruiting
First Posted : February 21, 2008
Last Update Posted : March 30, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leukemia, Myelogenous, Chronic Leukemia, Lymphoblastic, Acute Leukemia, Myelogenous, Acute Myeloproliferative-Myelodysplastic Diseases Lymphoma, Malignant | Drug: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients Drug: Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies Other: Hematopoietic Progenitor Cell Transplantation (HPCT) Radiation: CNS radiation treatment for ALL with prior CNS disease patients | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies |
Study Start Date : | March 2007 |
Estimated Primary Completion Date : | January 2020 |
Estimated Study Completion Date : | January 2020 |

- Drug: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients
Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.
Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.
Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2.
- Drug: Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
Busulfan administration:
- For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.
- For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.
- Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.
Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.
Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.
Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2.
- Other: Hematopoietic Progenitor Cell Transplantation (HPCT)
Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
- Radiation: CNS radiation treatment for ALL with prior CNS disease patients
Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.
Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:
- Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count
- Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count
- Evaluate the morbidity and mortality of hematopoietic progenitor cell transplantation (HPCT) at Children's Memorial Hospital. [ Time Frame: To study end ]
- Evaluate the effectiveness of graft versus host disease prevention with a combination of anti-thymocyte globulin, continuous infusion cyclosporine, and short course methotrexate for transplants. [ Time Frame: To study end ]
- Determine the toxicity of a single conditioning regimen consisting of total body irradiation, etoposide, and Cyclophosphamide for patients with transplant eligible lymphoid malignant conditions or myeloid malignant conditions receiving cord blood units. [ Time Frame: To study end ]
- Determine the toxicity of a single conditioning regimen consisting of Busulfan and Cyclophosphamide for patients with transplant eligible myeloid malignant conditions who are not receiving cord blood units. [ Time Frame: To study end ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Malignant Disease
- Chronic myleogenous leukemia in chronic or accelerated phase
-
Acute lymphoblastic leukemia (ALL)
- First remission high-risk ALL (Ph+, t( 4-11) infants).
- Second remission ALL, after a short first remission (<36 mos from Dx).
- 3rd or greater remission ALL.
-
Acute myelogenous leukemia (AML)
- First remission high risk acute nonlymphoblastic (ANLL) (as defined by cytogenetics), if a matched sibling donor is available.
- Initial partial remission AML (<20% blasts in the bone marrow).
- AML that is refractory to two cycles of induction therapy.
- Second or greater remission AML
-
Myelodysplastic/Myeloproliferative Disease
- Juvenile Myelomonocytic Leukemia (JMML)
- Myelosplastic syndrome and/or pre-leukemia at any stage
-
Lymphoma
- Relapsed lymphoma with residual disease that appears to be chemo-sensitive and non-bulky (<5 cm at largest diameter)
- Venous Access: Three lumens of central vascular access will be required for all patients entered on protocol due to the need for a dedicated line for continuous infusion cyclosporine.
- Informed Consent: The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained in accordance with the institutional policies approved by the U.S. Department of Health and Human Services.
-
Patient organ function requirements:
- Adequate renal function: Serum Creatinine <~1.5 x normal, or Creatinine clearance of 70 mL/min/1.73 mE2 or an equivalent GFR as determined by the institutional normal range
- Adequate liver function: Total bilirubin <1.5 x normal; and SGOT (AST) or SGPT (ALT) <~2.5 x normal
- Adequate cardiac function: Shortening fraction of >/=27% by echocardiogram
- Adequate pulmonary function: FEV1/FVC >/=60% by pulmonary function test; for children who are uncooperative, no evidence of dysnpea at rest, or exercise intolerance, and must have a pulse oximetry >94% in room air
- Performance status: Lansky for children </= 16 years >/= 60; Karnofsky status for those > 16 years of age >/= 70
- Effective Contraceptive Use: Women of childbearing potential and sexually active males should use effective contraception while on study.
Exclusion Criteria:
- Patients who are pregnant or lactating
- Inability to find a suitable donor for the patient
- Patient is HIV-positive
- Patient has active Hepatitis B
- Disease progression or relapse prior to HPC infusion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00619879
Contact: Morris Kletzel, MD | 773-880-4562 | mkletzel@northwestern.edu | |
Contact: Terriss Conterato | 773-880-8153 | TConterato@childrensmemorial.org |
United States, Illinois | |
Children's Memorial Hospital | Recruiting |
Chicago, Illinois, United States, 60614 | |
Principal Investigator: Morris Kletzel, MD |
Principal Investigator: | Morris Kletzel, MD | Ann & Robert H Lurie Children's Hospital of Chicago |
Responsible Party: | Morris Kletzel, MD, Children's Memorial Hospital |
ClinicalTrials.gov Identifier: | NCT00619879 |
Other Study ID Numbers: |
SCT 0307 |
First Posted: | February 21, 2008 Key Record Dates |
Last Update Posted: | March 30, 2011 |
Last Verified: | March 2011 |
Leukemia, Myelogenous, Chronic Leukemia, Lymphoblastic, Acute Leukemia, Myelogenous, Acute Myeloproliferative-Myelodysplastic Diseases Juvenile Myelomonocytic Leukemia Dysmyelopoietic Syndromes Lymphoma, Malignant Stem Cell Transplantation, Hematopoietic |
Allogeneic Transplantation Human Leukocyte Antigens Busulfan Total Body Irradiation VP-16 Etoposide Cyclophosphamide Graft-Versus-Host Disease |
Lymphoma Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, Lymphoid Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases |